Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis.
The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier.
It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators.
The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007.
Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 16, 20 | -0.11 Increased by +55.80% | -0.18 Increased by +38.61% |
| Aug 6, 20 | -0.17 Increased by +56.41% | -0.21 Increased by +20.00% |
| May 15, 20 | -0.19 Increased by +32.14% | -0.26 Increased by +25.49% |
| Mar 10, 20 | -0.23 Increased by +36.11% | -0.29 Increased by +20.00% |
| Nov 7, 19 | -0.25 Increased by +50.00% | -0.41 Increased by +38.53% |
| Aug 7, 19 | -0.39 Increased by +9.30% | -0.38 Decreased by -3.53% |
| May 8, 19 | -0.28 Increased by +12.50% | -0.36 Increased by +22.22% |
| Mar 8, 19 | -0.36 Increased by +28.00% | -0.40 Increased by +9.25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 20 | 0.00 Decreased by N/A% | -8.17 M Increased by +36.34% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 20 | 0.00 Decreased by N/A% | -8.89 M Increased by +55.57% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 20 | 0.00 Decreased by -100.00% | -9.88 M Increased by +31.49% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 19 | 0.00 Decreased by -100.00% | -11.86 M Increased by +29.85% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 19 | 0.00 Decreased by -100.00% | -12.83 M Increased by +30.36% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 19 | 0.00 Decreased by -100.00% | -20.02 M Decreased by -29.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 19 | 5.00 M Increased by +430.79% | -14.42 M Decreased by -30.76% | Decreased by -288.36% Increased by +75.36% |
| Dec 31, 18 | 1.78 M Increased by +10.05% | -16.90 M Increased by +62.84% | Decreased by -946.78% Increased by +66.23% |